Fluconazole for the treatment of candidiasis: 15 years experience

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 3, 2004, Pages 357-366

  Cha, Raymond ^a   Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candidemia; Candidiasis; Fluconazole; Oropharyngeal; Prophylaxis

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CORTICOSTEROID; CYTOCHROME P450 3A; CYTOTOXIC AGENT; ECHINOCANDIN B DERIVATIVE; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; MICAFUNGIN; NON PRESCRIPTION DRUG; NYSTATIN; PLACEBO; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; TINADERM M; TOLNAFTATE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CANDIDA; CANDIDIASIS; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG USE; ESOPHAGITIS; ESOPHAGUS; EXPERIENCE; FOOD DRUG INTERACTION; HUMAN; LIPOGENESIS; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PREVALENCE; REVIEW; SEPTICEMIA; THRUSH; VAGINA CANDIDIASIS;

EID: 2942519530     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.3.357     Document Type: Review

References (97)

1. Singh N. Invasive mycoses in organ transplant recipients: controversies in prophylaxis and management. J. Antimicrob. Chemother. 45(6), 749-755 (2000).
2. Bennett JE. Introduction to mycoses. In: Principles and Practice of Infectious Diseases, 5th edition. Mandell JL, Bennett JE, Dolin R (Eds). Churchill Livingstone, PA, USA, 2654-2656 (2000).
3. Beck Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infection in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167, 1247-1251 (1993).
4. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin. Infect. Dis. 18, 525-532 (1994).
5. Wey SB, Mori M, Pfaller MA et al. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch. Intern. Med. 149, 2349-2353 (1989).
6. Pfaller MA, Jones RN, Doern GV et al. National surveillance of nosocomial bloodstream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbiol. Infect. Dis. 31, 327-332 (1998).
7. Pappas PG, Rex JH, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 38(2), 161-189 (2004).
8. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325, 1274-1277 (1991).
9. Abi-Said D, Anaissie E, Uzun O et al. The epidemiology of hematogenous candidiasis caused by different Candidia species. Clin. Infect. Dis. 24, 1122-1128 (1997).
10. Komshian SV, Uwaydah AK, Sobel JD. Fungemia caused by Candidia spp. and Turolopsis glabrata in the hospitalized patient: frequency, characteristics and evaluation of factors influencing outcome. Rev. Infect. Dis. 11, 379-390 (1989).
11. Pfaller MA, Nosocomial candidiasis: emerging species, reservoirs and modes. Clin. Infect. Dis. 22, S89-S94 (1996).
12. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis and clinical disease with comparison to C. albicans. Clin. Microbiol. Rep. 12, 80-96 (1999).
13. Sobel JD, Vaginitis. N. Engl. J. Med. 337, 1896-1903 (1997).
14. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin. Infect. Dis. 26, 259-274 (1998).
15. Sobel JD. Treatment of vaginal candida infection. Exp. Opin. Pharmacother. 3(8), 1059-1065 (2002).
16. Fotos PG, Lilly JP. Clinical management of oral and perioral candidosis. Dermatol. Clin. 14(2), 273-280 (1996).
17. Minamoto GY, Rosenberg AS. Fungal infections in patients with acquired immunodeficiency syndrome. Med. Clin. North Am. 81(2), 381-409 (1997).
18. Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin. Ther. 20(1), 40-57 (1998).
19. Maddux MS, Barriere SL. A review of complications of amphotericin therapy: recommendation for prevention and management. Drug Intell. Clin. Pharm. 14, 177-181 (1980).
20. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents Chemother. 32, 1-8 (1988).
21. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39, 877-916 (1990).
22. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50, 658-690 (1995).
23. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330, 263-272 (1994).
24. Stevens DA. The new generation of antifungal drugs. Eur. J. Clin. Microbiol. Infect. Dis. 7, 732-735 (1988).
25. Blum RA, D'Andrea DT, Florentino BM et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann. Intern. Med. 114(9), 755-757 (1991).
26. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole (UK-49,858) in humans. Rev. Infect Dis. 12, S318-S326 (1990).
27. Drew RH, Perfect JR, Gallis HA. Use of fluconazole in a patient with documented malabsoportion of ketoconazole. Clin. Pharm. 7, 622-623 (1988).
28. Ebden P, Neill P, Farrow PR. Sputum levels of fluconazole in humans. Antimicrob. Agents Chemother. 33, 963-964. (1989).
29. Tucker RM, Williams PL, Arathoon EG et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidoidal meningitis. Antimicrob. Agents Chemother. 32, 369-373. (1988).
30. Foulds G, Wajszczuk C, Weidler DJ et al. Steady-state parenteral kinetics of fluconazole in man. Ann. NY Acad. Sci. 544, 427-430 (1988).
31. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin. Pharmacokinet. 33, 52-77 (1997).
32. Walsh TJ, Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur. J. Clin. Microbiol. Infect. Dis. 7, 460-475 (1988).
33. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal agent, in animals and humans. Antimicrob. Agents Chemother. 28, 648-653 (1985).
34. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy 10(Suppl.), 141-145 (1990).
35. Rex JH, Cooper WG Jr, Merz JN et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14, 643-658 (2001).
36. Cameron ML, Schell WA, Bruch S et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus Type I. Antimicrob. Agents Chemother. 37, 2449-2453 (1993).
37. Annaissie EF, Karyotakis NC, Hachem R et al. Correlation between in vitro and in vivo activity of antifungal agents against Candidia spp. J. Infect. Dis. 170, 384-389 (1994).
38. National Committee for Clinical Laboratory Standards, Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A National Committee for Clinical Laboratory Standards, Wayne, PA, USA, (1997).
39. Ramani R, Chaturvedi V. Proficiency testing program for clinical laboratory performing antifungal susceptibility testing of pathogenic yeast species. J. Clin. Mircobiol. 41, 1143-1146 (2003).
40. Morace G, Amato G, Bistoni F et al. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida spp. J. Clin. Microbiol. 40, 2953-2958 (2002).
41. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother 47(10), 3149-3154 (2003).
42. Rogers TE, Galgiani JN. Activity of fluconazole (UK 49,858) and ketoconazole against Candidia albicans in vitro and in vivo. Antimicrob. Agents Chemother. 30, 418-422 (1986).
43. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida spp. and distribution of species recovered from blood cultures over a 5-year period. Antimicrob. Agents Chemother. 38, 1422-1424 (1994).
44. Ohkawa M, Tokunaga S, Takashima M et al. In vitro susceptibility testing of Candida isolates from clinical specimens to four antifungal agents. Chemotherapy 36, 396-402 (1990).
45. Morace G, Manzara. S, Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Chemotherapy 37, 23-31 (1991).
46. Martin E, Parras P, del Carmen Lozano M. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole. Chemotherapy 38, 335-339 (1992).
47. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy 40, 92-98 (1994).
48. Arias A, Arevalo MP, Andreu A et al. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents. Mycoses 37, 285-289 (1994).
49. Pfaller MA, Messer SA, Gee S et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37(3), 870-872 (1999).
50. Espinel-Ingroff A, Pfaller M, Messer SA et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42(2), 718-721 (2004).
51. Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J. Antimicrob. Chemother. 19, 171-174 (1987).
52. Klepser ME, Wolfe EJ, Jones RN et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother 41, 1392-1395 (1997).
53. Burgess DS, Hastings RW, Summers KK et al. Pharmacodynamics of fluconazole, itraconazole and amphotericin B against Candida albicans. Diag. Microbiol. Infect. Dis. 36, 13-18 (2000).
54. Louie A, Drusano GL, Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents. Chemother. 42, 1105-1109 (1998).
55. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents. Chemother. 43, 2116-2120 (1999).
56. Van Etten EWM, can den Heuvel-de Groot C, Bakker-Woudenberg SJM. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J. Antimicrob. Chemother. 32, 723-739 (1993).
57. Walsh TJ, Aoki S, Mechinaud F et al. Effects of preventive, early and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J. Infect. Dis. 161, 755-760 (1990).
58. Cacciapuoti A, Loebengerg D, Parmegiani R et al. Comparison of SCH-39304, fluconazole and ketoconazole for the treatment of systemic infections in mice. Antimicrob. Agents Chemother. 36, 64-67 (1992).
59. Bannatyne RM, Cheng PC, Fong IW. Comparison of the efficacies of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candidia albicans infection in the neutropenic mouse. Infection 20, 168-170 (1992).
60. Richardson K, Brammer KW, Marriott MS et al. Activity of UK-49,858, a bistriazole derivative, against experimental infections with Candidia albicans and Trichophyton mentagrophytes. Antimicrob. Agents Chemother. 27(5), 832-835 (1985).
61. Sobel JD. Treatment of vaginal candida infections. Exp. Opin. Pharmacother. 3(8), 1059-1065 (2002).
62. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations. Am. J. Obstet. Gynecol. 178(2), 203-211 (1998).
63. Haefner HK. Current evaluation and management of vulvovaginitis. Clin. Obstet. Gynecol. 42(2), 184-195 (1999).
64. Clinical Effectiveness Group. National guideline for the management of vulvovaginal candidiasis. Sex. Transm. Infect. 75(Suppl. 1), S19-S20 (1999).
65. Tooley PJ. Patient and doctor preferences in the treatment of vaginal candidiasis. Practitioner 229, 655-662 (1985).
66. Edelman DA, Grant S. One-day therapy for vaginal candidiasis. A review. J. Reprod. Med. 44, 543-547 (1999).
67. Sobel JD, Kapernick PS, Zervos M et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am. J. Obstet. Gynecol. 185(2), 363-369 (2001).
68. Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. Drugs 63(11), 1059-1066 (2003).
69. Schuman P, Capps L, Peng G et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann. Intern. Med. 126(9), 689-696 (1997).
70. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect. Dis. Clin. North Am. 16(4), 793-820 (2002).
71. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy 19(1), 76-87 (1999).
72. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin. Infect. Dis. 26, 259-274 (1998).
73. Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin. Ther. 20(1), 40-57 (1998).
74. Graybill JR, Vizques J, Darouiche RO et al. Itraconazole oral solution: a novel and effective treatment for oropharyngeal candidiasis in HIV/AIDS patients. Am. J. Med. 104, 33-39 (1998).
75. Powderly WG, Mayer KH, Perfect JR. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res. Hum. Retroviruses 15, 1405-1412 (1999).
76. Vazquez JA. Invasive oesophageal candidiasis: current and developing treatment options. Drugs. 63(10), 971-989 (2003).
77. Arathoon EG, Gotuzzo E, Noriega LM et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46(2), 451-457 (2002).
78. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33(9), 1447-1454 (2001).
79. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331(20), 1325-1330 (1994).
80. Phillips P, Shafran S, Garber G et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur. J. Clin. Microbiol. Infect. Dis. 16(5), 337-345 (1997).
81. Anaissie EJ, Rex JH, Uzun O et al. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. 104, 238-245 (1998).
82. Nguyen MH, Peacock JE, Tanner DC et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch. Intern. Med. 155, 2429-2435 (1995).
83. Rex JH, Pappas PG, Karchmer AW et al. A. randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin. Infect. Dis. 36(10), 1221-1228 (2003).
84. Van Burik J, Ratanatharathorn V, Lipton J et al. Randomized, double-blind trial of micafungin versus fluconazole for the prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant, NIAID/BAMSG Protocol 46. 41st Interscience Conference Antimicrob. Agents Chemother. Am. Soc. Microbiol. (2001) (Abstract M1238).
85. Walsh T, Sable C, Depauw B et al. A randomized, double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. 41st Interscience Conference Antimicrob. Agents Chemother. Am. Soc. Microbiol. (2001) (Abstract M1761).
86. Edwards DE. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. 25, 43-59 (1997).
87. Winston DJ, Hathorn JW, Schuster MG et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. J. Med. 108(4), 282-289 (2000).
88. Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control. J. Antimicrob. Chemother 41(Suppl. D), 95-105 (1998).
89. Malik IA, Moid I, Aziz Z et al. A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am. J. Med. 105, 478-483 (1998).
90. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care. Med. 27(6), 1066-1072 (1999).
91. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131(10), 729-737 (1999).
92. Garbino J, Lew DP, Romand JA et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 28(12), 1708-1717 (2002).
93. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically-ill surgical patients. Ann. Surg. 233(4), 542-548 (2001).
94. CuttnerJ, Troy KM, Fumaro, L et al. Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Results of a double-blind study. Am. J. Med. 81, 771-774 (1986).
95. DeGregorio MW, Lee WMF, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 50, 2780-2784 (1982).
96. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infection in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326, 845-851 (1992).
97. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. 171, 1545-1552 (1995).